A lab technician inspects filled vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020. Picture taken March 11, 2020.
Gilead Sciences Inc | Reuters
Gilead Sciences said Monday that results from a phase 3 trial showed its antiviral drug remdesivir helped patients with moderate Covid-19.
The trial compared patients on either a five-day or 10-day course of remdesivir plus standard of care versus standard of care alone. Patients on a five-day course were 65% more likely to have clinical improvement at day 11 versus standard of care, according to Gilead.
The odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care were also favorable, but not statistically significant, the company said.
“We now have three randomized, controlled clinical trials demonstrating that remdesivir improved clinical outcomes by several different measures,” Gilead’s Chief Medical Officer Dr. Merdad Parsey said in a statement. “Today’s results showed that when treating moderate disease, a 5-day course of remdesivir led to greater clinical improvement than standard of care, adding further evidence of remdesivir’s benefit to previously released study results.”
The stock was down more than 1% in premarket trading following the news.
This is a developing story. Please check back for updates.